Back to top
more

XOMA (XOMA)

(Delayed Data from NSDQ)

$25.48 USD

25.48
17,398

+0.89 (3.62%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $25.14 -0.34 (-1.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XOMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

XOMA Corporation [XOMA]

Reports for Purchase

Showing records 1 - 20 ( 328 total )

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

03/11/2024

Company Report

Pages: 8

A Position of Shopping Strength and Royalty Growth; 2023 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

02/16/2024

Daily Note

Pages: 7

Creativity in Value Creation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

01/18/2024

Daily Note

Pages: 7

Another Right Place, Right Time Transaction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

12/22/2023

Company Report

Pages: 7

Our XOMA All Grown Up; Big Win for Cash Balance and Business Model; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for XOMA 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

11/07/2023

Company Report

Pages: 7

3Q23 Results; Diverse Pipeline Supported by Growing Revenue; Shopping Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

10/31/2023

Company Report

Pages: 7

Third Vabysmo Approval, A Day One Check, and A Strategic Move; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

10/10/2023

Daily Note

Pages: 6

Third Indication For Vabysmo Seems Not Too Far Off; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

09/13/2023

Company Report

Pages: 7

Vabysmo Royalty Cash Flow Pushing Forward Nicely; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

08/09/2023

Company Report

Pages: 8

2Q23 Results; Inbounds at Highest Levels as Royalties Grow; Target Upped to $74

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

06/22/2023

Daily Note

Pages: 6

Near-Term Potential Royalty Addition Continues to Highlight Aggregation Model; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

06/15/2023

Daily Note

Pages: 6

IXINITY Reach Should Broaden and Hit XOMA''s Bottom Line; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

03/30/2023

Daily Note

Pages: 5

New Partner, More Royalties; Hematology Portfolio Expands With the Addition of IXINITY

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

03/10/2023

Company Report

Pages: 7

2022 Results; Business Model Begins to Bear Fruit With Recent Asset Approval and Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

11/22/2022

Company Report

Pages: 8

Check a Nice One Off the Shopping List; Organon to Drive Clinical Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

11/03/2022

Company Report

Pages: 6

3Q22 Results; Royalties Start Flowing and Shopping Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

09/29/2022

Company Report

Pages: 6

Sustained Revenue Line Taking Real Form; Faricimab Market Expands Into Europe

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

08/04/2022

Company Report

Pages: 6

2Q22 Results; Partnered Assets Continue to Make Headway as Asset Portfolio Matures

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

05/05/2022

Company Report

Pages: 8

1Q22 Results; All RIZE for Positive Phase 2b Readout in CHI from Partnered Asset

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

05/02/2022

Company Report

Pages: 8

All RIZE for Positive Phase 2b Readout in CHI from XOMA Partnered Asset

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party